NEW YORK (GenomeWeb News) – The Ontario Institute for Cancer Research said today that it will collaborate with Johnson & Johnson company Janssen to conduct clinical trials aimed at identifying new prostate cancer biomarkers.

Under the multi-center collaboration, the partners will seek to unearth biomarkers that identify patients with hormone-resistant prostate cancer who are at high risk for disease progression and biomarkers for predicting how patients will respond to therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.